Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-510US1	Application No. 10/579,545
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Andrew Baxter et al.	
		Filing Date May 16, 2006	Group Art Unit 1625

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,962,462	10/05/1999	Mills et al.			
	AB	US-2006-0252751-A1	11/09/2006	Xue et al.			
	AC	US-2007-0203230-A1	08/30/2007	Hossain			
	AD	US-2007-0203229-A1	08/30/2007	Hossain			
	AE	US 2007-0249648 A1	10/25/2007	Bladh et al.			
	AF	US-2007-0123543-A1	05/31/2007	Hossain et al.			
	AG	US-2007-0099945-A1	05/03/2007	Hossain et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	AH	WO 01/98273	12/27/2001	WIPO				
	AI	WO 2004/041279	05/21/2004	WIPO				
	AJ	WO 2005/049620	06/02/2005	WIPO				
	AK	WO 2005/092895	10/06/2005	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AL	Brown et al., "Novel CCR1 antagonists with improved metabolic stability", *Bioorg. Med. Chem. Lett.*14:2175-2179 (2004)
	AM	Chen et al., "Heterodimerization and cross-desensitization between the μ-opioid receptor and the chemokine CCR5 receptor", *Eur. J. Pharmacol.* 483:175-186 (2004)
	AN	Dorwald F.Z. *Side Reactions in Organic Synthesis.* Wiley: VCH, Weinheim, 2005. p. IX of Preface
	AO	Godessart N., "Chemokine Receptors: Attractive Targets for Drug Discovery", *Ann. N.Y. Acad. Sci.* 1051:647-657 (2005)
	AP	Knochel et al., "Highly Functionalized Organomagnesium Reagents Prepared through Haolgen-Metal Exchange", *Angew. Chem. Int. Ed.* 42:4302-4320 (2003)
	AQ	Li J.J. "Grignard reaction." in: *Name Reactions: A Collection of Detailed Reaction Mechanisms* Third Expanded Edition Springer 2006, pp. 271-272
	AR	Martin et al., "Do Structurally Similar Molecules Have Similar Biological Activity?", *J. Med. Chem.* 45:4350-4358 (2002)
	AS	Pozharskii et al., *Heterocycles in Life and Society.* Wiley, 1997, pp. 1-6

Examiner Signature	Date Considered
/Charanjit Aulakh/	08/12/2008

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-510US1	Application No. 10/579,545
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Andrew Baxter et al.	
	Filing Date May 16, 2006	Group Art Unit 1625

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AT	Thoma et al., "Orally Bioavailable Competitive CCR5 Antagonists", *J. Med. Chem.* 47:1939-1955 (2004)
	AU	Thomson et al., *The Cytokine Handbook*, 4th ed. New York, Academic Press, 2003, pp. 1084-1087
	AV	Ting et al., "The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: Antagonists versus agonists", *Bioorg. Med. Chem. Lett.*15:3020-3023 (2005)
	AW	Xie et al., "Identification of novel series of human CCR1 antagonists", *Bioorg. Med. Chem. Lett.* 18:2215-2221 (2008)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/

Examiner Signature /Charanjit Aulakh/	Date Considered 08/12/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	